Estrogen metabolism and risk of breast cancer: A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women

Paola Muti, H. Leon Bradlow, Andrea Micheli, Vittorio Krogh, Jo L. Freudenheim, Holger J. Schünemann, Martin Stanulla, Jun Yang, Daniel W. Sepkovic, Maurizio Trevisan, Franco Berrino

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

Experimental and clinical evidence suggests that 16α-hydroxylated estrogen metabolites, biologically strong estrogens, are associated with breast cancer risk, while 2-hydroxylated metabolites, with lower estrogenic activity, are weakly related to this disease. This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16α-hydroxyestrone, in a prospective nested case-control study. Between 1987 and 1992, 10,786 women (ages 35-69 years) were recruited to a prospective study on breast cancer in Italy, the 'Hormones and Diet in the Etiology of Breast Cancer' (ORDET) study. Women with a history of cancer and women on hormone therapy were excluded at baseline. At recruitment, overnight urine was collected from all participants and stored at -80°C. After an average of 5.5 years of follow-up, 144 breast cancer cases and four matched controls for each case were identified among the participants of the cohort. Among premenopausal women, a higher ratio of 2-hydroxyestrone to 16α-hydroxyestrone at baseline was associated with a reduced risk of breast cancer: women in the highest quintile of the ratio had an adjusted odds ratio (OR) for breast cancer of 0.58 [95% confidence interval (CI) = 0.25-1.34]. The corresponding adjusted OR in postmenopausal women was 1.29 (95% CI = 0.53-3.10). Results of this prospective study support the hypothesis that the estrogen metabolism pathway favoring 2-hydroxylation over 16α-hydroxylation is associated with a reduced risk of invasive breast cancer risk in premenopausal women.

Original languageEnglish
Pages (from-to)635-640
Number of pages6
JournalEpidemiology
Volume11
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

Estrogens
Prospective Studies
Breast Neoplasms
Hydroxylation
Odds Ratio
Hormones
Confidence Intervals
2-hydroxyestrone
16-hydroxyestrone
Italy
Case-Control Studies
Urine
Diet
Neoplasms

Keywords

  • Breast neoplasms
  • Cohort study
  • Estrogen metabolites
  • Estrogens

ASJC Scopus subject areas

  • Epidemiology

Cite this

Estrogen metabolism and risk of breast cancer : A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. / Muti, Paola; Bradlow, H. Leon; Micheli, Andrea; Krogh, Vittorio; Freudenheim, Jo L.; Schünemann, Holger J.; Stanulla, Martin; Yang, Jun; Sepkovic, Daniel W.; Trevisan, Maurizio; Berrino, Franco.

In: Epidemiology, Vol. 11, No. 6, 2000, p. 635-640.

Research output: Contribution to journalArticle

Muti, P, Bradlow, HL, Micheli, A, Krogh, V, Freudenheim, JL, Schünemann, HJ, Stanulla, M, Yang, J, Sepkovic, DW, Trevisan, M & Berrino, F 2000, 'Estrogen metabolism and risk of breast cancer: A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women', Epidemiology, vol. 11, no. 6, pp. 635-640. https://doi.org/10.1097/00001648-200011000-00004
Muti, Paola ; Bradlow, H. Leon ; Micheli, Andrea ; Krogh, Vittorio ; Freudenheim, Jo L. ; Schünemann, Holger J. ; Stanulla, Martin ; Yang, Jun ; Sepkovic, Daniel W. ; Trevisan, Maurizio ; Berrino, Franco. / Estrogen metabolism and risk of breast cancer : A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. In: Epidemiology. 2000 ; Vol. 11, No. 6. pp. 635-640.
@article{6081638015b9499491a248eb94ca95ed,
title = "Estrogen metabolism and risk of breast cancer: A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women",
abstract = "Experimental and clinical evidence suggests that 16α-hydroxylated estrogen metabolites, biologically strong estrogens, are associated with breast cancer risk, while 2-hydroxylated metabolites, with lower estrogenic activity, are weakly related to this disease. This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16α-hydroxyestrone, in a prospective nested case-control study. Between 1987 and 1992, 10,786 women (ages 35-69 years) were recruited to a prospective study on breast cancer in Italy, the 'Hormones and Diet in the Etiology of Breast Cancer' (ORDET) study. Women with a history of cancer and women on hormone therapy were excluded at baseline. At recruitment, overnight urine was collected from all participants and stored at -80°C. After an average of 5.5 years of follow-up, 144 breast cancer cases and four matched controls for each case were identified among the participants of the cohort. Among premenopausal women, a higher ratio of 2-hydroxyestrone to 16α-hydroxyestrone at baseline was associated with a reduced risk of breast cancer: women in the highest quintile of the ratio had an adjusted odds ratio (OR) for breast cancer of 0.58 [95{\%} confidence interval (CI) = 0.25-1.34]. The corresponding adjusted OR in postmenopausal women was 1.29 (95{\%} CI = 0.53-3.10). Results of this prospective study support the hypothesis that the estrogen metabolism pathway favoring 2-hydroxylation over 16α-hydroxylation is associated with a reduced risk of invasive breast cancer risk in premenopausal women.",
keywords = "Breast neoplasms, Cohort study, Estrogen metabolites, Estrogens",
author = "Paola Muti and Bradlow, {H. Leon} and Andrea Micheli and Vittorio Krogh and Freudenheim, {Jo L.} and Sch{\"u}nemann, {Holger J.} and Martin Stanulla and Jun Yang and Sepkovic, {Daniel W.} and Maurizio Trevisan and Franco Berrino",
year = "2000",
doi = "10.1097/00001648-200011000-00004",
language = "English",
volume = "11",
pages = "635--640",
journal = "Epidemiology",
issn = "1044-3983",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Estrogen metabolism and risk of breast cancer

T2 - A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women

AU - Muti, Paola

AU - Bradlow, H. Leon

AU - Micheli, Andrea

AU - Krogh, Vittorio

AU - Freudenheim, Jo L.

AU - Schünemann, Holger J.

AU - Stanulla, Martin

AU - Yang, Jun

AU - Sepkovic, Daniel W.

AU - Trevisan, Maurizio

AU - Berrino, Franco

PY - 2000

Y1 - 2000

N2 - Experimental and clinical evidence suggests that 16α-hydroxylated estrogen metabolites, biologically strong estrogens, are associated with breast cancer risk, while 2-hydroxylated metabolites, with lower estrogenic activity, are weakly related to this disease. This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16α-hydroxyestrone, in a prospective nested case-control study. Between 1987 and 1992, 10,786 women (ages 35-69 years) were recruited to a prospective study on breast cancer in Italy, the 'Hormones and Diet in the Etiology of Breast Cancer' (ORDET) study. Women with a history of cancer and women on hormone therapy were excluded at baseline. At recruitment, overnight urine was collected from all participants and stored at -80°C. After an average of 5.5 years of follow-up, 144 breast cancer cases and four matched controls for each case were identified among the participants of the cohort. Among premenopausal women, a higher ratio of 2-hydroxyestrone to 16α-hydroxyestrone at baseline was associated with a reduced risk of breast cancer: women in the highest quintile of the ratio had an adjusted odds ratio (OR) for breast cancer of 0.58 [95% confidence interval (CI) = 0.25-1.34]. The corresponding adjusted OR in postmenopausal women was 1.29 (95% CI = 0.53-3.10). Results of this prospective study support the hypothesis that the estrogen metabolism pathway favoring 2-hydroxylation over 16α-hydroxylation is associated with a reduced risk of invasive breast cancer risk in premenopausal women.

AB - Experimental and clinical evidence suggests that 16α-hydroxylated estrogen metabolites, biologically strong estrogens, are associated with breast cancer risk, while 2-hydroxylated metabolites, with lower estrogenic activity, are weakly related to this disease. This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16α-hydroxyestrone, in a prospective nested case-control study. Between 1987 and 1992, 10,786 women (ages 35-69 years) were recruited to a prospective study on breast cancer in Italy, the 'Hormones and Diet in the Etiology of Breast Cancer' (ORDET) study. Women with a history of cancer and women on hormone therapy were excluded at baseline. At recruitment, overnight urine was collected from all participants and stored at -80°C. After an average of 5.5 years of follow-up, 144 breast cancer cases and four matched controls for each case were identified among the participants of the cohort. Among premenopausal women, a higher ratio of 2-hydroxyestrone to 16α-hydroxyestrone at baseline was associated with a reduced risk of breast cancer: women in the highest quintile of the ratio had an adjusted odds ratio (OR) for breast cancer of 0.58 [95% confidence interval (CI) = 0.25-1.34]. The corresponding adjusted OR in postmenopausal women was 1.29 (95% CI = 0.53-3.10). Results of this prospective study support the hypothesis that the estrogen metabolism pathway favoring 2-hydroxylation over 16α-hydroxylation is associated with a reduced risk of invasive breast cancer risk in premenopausal women.

KW - Breast neoplasms

KW - Cohort study

KW - Estrogen metabolites

KW - Estrogens

UR - http://www.scopus.com/inward/record.url?scp=0033788285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033788285&partnerID=8YFLogxK

U2 - 10.1097/00001648-200011000-00004

DO - 10.1097/00001648-200011000-00004

M3 - Article

C2 - 11055622

AN - SCOPUS:0033788285

VL - 11

SP - 635

EP - 640

JO - Epidemiology

JF - Epidemiology

SN - 1044-3983

IS - 6

ER -